AAPS Science360

The Boston Society is pleased to announce that the Boston Society Gene & Cell Therapy Conference (BSG&CT) 2026 will take place March 19–20, 2026 at Bristol Myers Squibb in Cambridge, Massachusetts, in partnership with AAPS. 

This collaboration reflects a shared commitment to advancing rigorous, science-driven dialogue across the rapidly evolving gene and cell therapy landscape. The 2026 meeting will convene leaders from industry, academia, regulatory affairs, translational science, clinical development, and manufacturing to address the most pressing challenges and innovations shaping the field. 

Confirmed Plenary Speakers Include: 

• Dr. Panteli Theocharous, FIBMS, M.S., PhD, FRCPath, CEO, VectorGen  

• Palani Palaniappan, PhD, Chief Technical Operations & Quality Officer, Flagship Pioneering 

• Omar Abudayyeh, PhD, Assistant Professor at Harvard Medical School / Brigham and Women’s Hospital / MGB Gene and Cell Therapy Institute  

Additional Confirmed Speakers: 

• Prof. Mimoun Azzouz, University of Sheffield – Gene Therapy Ecosystem at The University of Sheffield 

• Amy Rosenberg, MD, Senior Director Regulatory Affairs, Regeneron – Success of CAR-T Cells in Treatment of Autoimmunity: Broader Application to Disease Treatment & Prevention Including Immunogenicity of Therapeutic Proteins  

• Eva Andres-Mateos, PhD, Associated VP Preclinical Development Gene Therapy, Eli Lilly – Translational sciences for GT/clinical data – talk title TBA  

• Brian Furmanski, PhD, Chief Regulatory Officer, Kriya Therapeutics – The Path to First-in-Human: Regulatory and Strategic Considerations for CGT IND Submissions  

• Aman Singh, PhD, Group Director – Clinical Pharmacology & Pharmacometrics, Johnson & Johnson – SLE CAR-T Modeling – talk title TBA  

• Matt Silva, PhD, CEO, EMIT Imaging – Cryo-Fluorescence Tomography: Transformative 3D Imaging for Gene & Cell Therapy  

• Joleen White, PhD, BioData Solutions – Immunogenicity in Cell and Gene Therapy: Risk Assessment, Assays, and IVDR Implications  

• Mandy Xie, PhD, Executive Director, Head of Analytical Development & Attribute Science, Bristol Myers Squibb – Insight into Operational Efficiencies around CART Manufacturing – Title TBA  

• Stephen Wang, PhD, Associate Director, Novartis Gene Therapies – Preclinical and Clinical Regulatory Aspects of the Autologous Hematopoietic Stem Cell (HSC) Delivery of DFT383 for Nephropathic Cystinosis – Title TBA 

• Shashi Ramaiah, PhD, President, Founder, and CEO, SPECCRO, Inc. – Derisking Gene Therapy (AAV): Translational Strategies and Emerging Tools to Navigate Safety Risks  

The 2026 conference is sponsored by EMIT Imaging, Boston BioProducts, JOINN, Proteintech,and Biomere, and is organized by The Boston Society in partnership with AAPS  

By bringing together technical operations leaders, regulatory experts, translational scientists, clinical pharmacology specialists, and emerging technology innovators, BSG&CT 2026 will provide a focused forum for advancing practical solutions across gene and cell therapy development. 

Registration details, sponsorship opportunities, and program updates are available at: 
https://www.bostonsociety.org/Conference/.